Viral Hepatitis: Review of Arthritic Complications and Therapy for Arthritis in the Presence of Active HBV/HCV


DOI: 10.1007/s11926-013-0319-1

Cite this article as:
Vassilopoulos, D. & Calabrese, L.H. Curr Rheumatol Rep (2013) 15: 319. doi:10.1007/s11926-013-0319-1
Part of the following topical collections:
  1. Topical Collection on Infections and Arthritis


Chronic infection with hepatitis B (HBV) or C (HCV) virus, which currently affect approximately 7 % of the world population, is encountered with the same frequency among patients with arthritis starting biological or non-biological disease-modifying anti-rheumatic drugs (DMARDs). Treatment with biological agents, including anti-tumor necrosis factor agents, rituximab, and abatacept, without appropriate antiviral therapy has been associated with reactivation of HBV infection which in some cases can lead to life-threatening complications, indicating the need for appropriate screening and treatment of these patients. In this review, the latest data regarding HBV or HCV-related arthritic complications and treatment of rheumatic diseases in the presence of chronic HBV or HCV infection will be critically presented.


Hepatitis B virus HBV Hepatitis C virus HCV Viral hepatitis Arthritis Rheumatoid arthritis Disease-modifying anti-rheumatic drugs DMARDs Biological agents Cryoglobulinemic vasculitis Interferon-a Ribavirin Protease inhibitors Rituximab Abatacept Anti-tumor necrosis factor agents Therapy 

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Dimitrios Vassilopoulos
    • 1
  • Leonard H. Calabrese
    • 2
  1. 1.2nd Department of Medicine, Hippokration General HospitalAthens University School of MedicineAthensGreece
  2. 2.Cleveland Clinic Lerner College of MedicineCase Western Reserve UniversityClevelandUSA

Personalised recommendations